Andamertinib

Andamertinib
Clinical data
Other namesGTPL13732, PLB1004
Legal status
Legal status
  • Rx in China
Identifiers
  • N-[4-Methoxy-2-[4-(3-methoxyazetidin-1-yl)piperidin-1-yl]-5-[[6-(1-methylindazol-5-yl)pyrimidin-4-yl]amino]phenyl]prop-2-enamide
CAS Number
PubChem CID
IUPHAR/BPS
UNII
Chemical and physical data
FormulaC31H36N8O3
Molar mass568.682 g·mol−1
3D model (JSmol)
  • CN1C2=C(C=C(C=C2)C3=CC(=NC=N3)NC4=C(C=C(C(=C4)NC(=O)C=C)N5CCC(CC5)N6CC(C6)OC)OC)C=N1
  • InChI=1S/C31H36N8O3/c1-5-31(40)36-25-13-26(29(42-4)15-28(25)38-10-8-22(9-11-38)39-17-23(18-39)41-3)35-30-14-24(32-19-33-30)20-6-7-27-21(12-20)16-34-37(27)2/h5-7,12-16,19,22-23H,1,8-11,17-18H2,2-4H3,(H,36,40)(H,32,33,35)
  • Key:KKPCZGCBAIJCOU-UHFFFAOYSA-N

Andamertinib is pharmaceutical drug developed by Avistone Biotechnology for the treatment of non-small-cell lung cancer (NSCLC). It is an epidermal growth factor receptor (EGFR) antagonist. Andamertinib is an irreversible EGFR inhibitor designed to target EGFR with exon 20 insertion mutations.

Use

In April 2026, andamertinib received conditional approval in China for adult patients with locally advanced or metastatic NSCLC who have experienced disease progression during or following platinum-based chemotherapy, or who are intolerant to platinum-based chemotherapy, and who have been confirmed by testing to have an EGFR exon 20 insertion mutation.

Clinical trials

The following clinical trials are evaluating andamertinib for treating NSCLC:

References

  1. ↑ Yang JJ, Mu Y, Wang ZH, Duan JC, Zhang Y, Wu L, et al. (March 2026). "Andamertinib in Advanced NSCLC With EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results From the Phase 2 KANNON Study". Journal of Thoracic Oncology. 21 (3) 103518. doi:10.1016/j.jtho.2025.11.008. PMID 41248848.
  2. ↑ Zhao J, Xu W, Zhou F, Zhang X, Zhou M, Miao D, et al. (January 2026). "Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches". Nature Reviews. Clinical Oncology. 23 (1): 63–83. doi:10.1038/s41571-025-01085-z. PMID 41219394.
  3. ↑ "Andamertinib - Avistone Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
  4. ↑ "Andamertinib | Ligand page". IUPHAR/BPS Guide to PHARMACOLOGY.
  5. ↑ Blair HA (2026). "Andamertinib: First Approval". Drugs. doi:10.1007/s40265-026-02375-1. PMID 42616343.
  6. ↑ Clinical trial number NCT07336732 for "Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations" at ClinicalTrials.gov
  7. ↑ Clinical trial number NCT06574347 for "Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC." at ClinicalTrials.gov
  8. ↑ Clinical trial number NCT06970782 for "Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure" at ClinicalTrials.gov